Navigation Links
Gerresheimer Continues Expansion Course
Date:5/23/2008

Prospects for 2008 Confirmed

Shareholders Approve Dividend Payment of EUR 0.40 per Share

DUSSELDORF, Germany, May 23 /PRNewswire-FirstCall/ -- The company ended the financial year 2007 with a positive result. In 2007 Gerresheimer achieved sales of EUR957.7m and operating earnings (adjusted EBITDA) of EUR181.6m. For the first quarter of the current financial year 2008, the company reports a sales increase of 18.2% to EUR 239.1m, with a 20.4% increase in operating earnings (adjusted EBITDA) to EUR 43.0m.

"In the past year we have expanded our regional presence with consistent focus on the high-profit business in specialty products for the pharmaceutics and life-science industry. We intend to continue this successful strategy in 2008," says Dr. Axel Herberg, CEO of Gerresheimer AG.

At the Shareholders' Meeting in Dusseldorf today, Dr. Herberg confirmed the positive prospects for 2008. In the coming year the company aims to achieve sales growth of 14%-16% and an Adjusted EBITDA margin in excess of 19%.

By a large majority the shareholders of Gerresheimer AG approved the actions of the Management Board and Supervisory Board for the financial year 2007 and a dividend payment of EUR0.40 per share. In the first year after its stock-exchange flotation Gerresheimer is therefore already distributing a sum of EUR12.6m to its shareholders.

By a large majority the shareholders also authorised the Management Board of Gerresheimer AG to issue warrant-linked bonds and convertible bonds up to the value of EUR500m in conjunction with the creation of contingent capital. They thereby supported the continued expansion course of the Dusseldorf supplier to the pharma and life-science industry.

A large number of shareholders and shareholder representatives attended the first Shareholders' Meeting of Gerresheimer AG after the IPO in June 2007, so 59% of the capital stock was represented at the Shareholders' Meeting.

Gerresheimer facts and figures

Gerresheimer employs more than 10,800 people in 41 production locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR 957.7m. The product portfolio ranges from pharmaceutical vials made of glass and plastic to complex drug delivery systems for the pharma and life-science industry. It includes sterile syringes, inhalers and other system-based approaches for safe dosage and application of medicines. The Group has a leading position in markets which are characterised by high technical and regulatory barriers.

Contact Press:

Burkhard Lingenberg,

Director Corporate PR & Marketing,

Telephone +49-211-6181-250,

Telefax +49-211-6181-241,

e-mail b.lingenberg@gerresheimer.com .

Contact Investor Relations:

Anke Linnartz,

Director Corporate Investor Relations,

Telephone +49-211-6181-314,

Telefax +49-211-6181-121,

e-mail a.linnartz@gerresheimer.com .


'/>"/>
SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Blackstone Sells Gerresheimer Stake
2. Standard & Poors Raises Gerresheimer Rating to BB+
3. Gerresheimer Starts the Year Successfully in 2008
4. Gerhard Schulze New Chairman of the Supervisory Board of Gerresheimer AG
5. Gerresheimer Finalises Purchase of Spanish Company EDP
6. Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America
7. Linnartz New Head of Investor Relations of Gerresheimer
8. Growth Trend for Gerresheimer Continues Unabated - Debt Reduction
9. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
10. Project HOPE to Send Humanitarian Assistance to China as Humanitarian Assistance to Myanmar Continues
11. AlphaRxs Indaflex(TM) Continues its Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: